Ophthalmic Business News

Femtosecond laser image-guided high-precision trabeculotomy, or FLigHT, for primary open-angle glaucoma showed positive safety and efficacy results in a first-in-human study, according to a press release from ViaLase.

Johnson & Johnson Vision received CE mark approval for the Elita femtosecond laser system, which corrects myopia in patients with or without astigmatism through the SILK procedure, according to a press release.

A post hoc analysis of data from the GATHER1 and GATHER2 clinical trials showed that avacincaptad pegol achieved positive results in vision loss reduction in patients with geographic atrophy, according to a press release from Iveric Bio.

Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.

The Consolidated Appropriations Act of 2023, enacted on Dec. 29, 2022, includes the Secure 2.0 Act of 2022, which contains many provisions designed to expand retirement coverage, increase retirement savings and clarify retirement rules.

Treatment-related serious adverse events in ocular safety, the primary endpoints in a 12-month safety clinical trial of reproxalap for the treatment of dry eye disease, were not observed, according to an Aldeyra Therapeutics press release.

EyePoint Pharmaceuticals and Rallybio have entered into a research collaboration to investigate sustained delivery of Rallybio’s complement C5 inhibitor using EyePoint’s Durasert technology.

TAMPA, Fla. — In this Healio Video Perspective from the Telling It Like It Is meeting, Brian M. Shafer, MD, discusses the upcoming launch and benefits of Iheezo topical ocular anesthetic.

Glaukos submitted a new drug application to the FDA for the iDose TR, a microinvasive intraocular implant designed to continuously deliver a travoprost formulation for the treatment of glaucoma.

The FDA accepted for priority review the biologics license application for aflibercept 8 mg for the treatment of wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy, according to a Regeneron press release.